Navigation Links
Engineering a protein to prevent brain damage from toxic agents
Date:7/30/2014

Research at New York University is paving the way for a breakthrough that may prevent brain damage in civilians and military troops exposed to poisonous chemicalsparticularly those in pesticides and chemical weapons.

An article in the current issue of the journal ChemBioChem outlines the advancement in detoxifying organophosphates, which are compounds commonly used in pesticides and warfare agents. The patent-pending process was developed by NYU School of Engineering Associate Professor of Chemical and Biological Engineering Jin Kim Montclare, along with Richard Bonneau, an associate professor in NYU's Department of Biology and a member of the computer science faculty at NYU's Courant Institute of Mathematical Sciences.

Their work centers on proteins called phosphotriesterases, which have the unique capability of degrading chemicals in a class known as organophosphates, which are found in everything from industrial pesticides to the sarin gas used in chemical warfare.

Organophosphates permanently bond to neurotransmitters in the brain, interfering with their ability to function and causing irreversible damage. The ability of phosphotriesterases to detoxify organophosphates has been previously documented; however, applications using the protein for this purpose have been limited by its short half-life and instability at high temperatures.

Montclare and her colleagues devised a method of re-engineering phosphotriesterases by incorporating an artificial fluorinated amino acid and computational biology. The result: a thermo-stable protein with a longer half-life that retains all the detoxification capabilities of the original version.

"Organophosphates pose tremendous danger to people and wildlife, and sadly it's not unusual for humans to come into contact with these compounds, whether through exposure to pesticide or an intentional chemical warfare attack," explained Montclare. "We've known that phosphotriesterases had the power to detoxify these nerve agents, but they were far too fragile to be used therapeutically," she said.

In a process that married computational biology and experimentation, the collaborators used Rosetta computational modeling software to identify sequences in the fluorinated phosphotriesterase protein that could be modified to increase its stability and make therapeutic applications a reality.

The possibilities for this reengineered protein are considerable. Montclare explained that in addition to therapeutic formulations, which could prevent nerve damage in the event of a gas attack or pesticide exposure and would likely be developed first for military use, the proteins could be critical when stores of toxic nerve agents need to be decommissioned.

"Oftentimes, chemical agent stockpiles are decommissioned through processes that involve treatment with heat and caustic chemical reagents for neutralization, followed by hazardous materials disposal," she said. "These proteins could accomplish that same task enzymatically, without the need for reactors and formation of dangerous byproducts."

Plans are under way to begin developing therapeutic applications for this modified phosphotriesterase, and the research team believes that its methodologyusing computational biology to identify potentially beneficial modifications to proteinscould point the way to future breakthroughs in engineered proteins.


'/>"/>

Contact: Kathleen Hamilton
kathleen.hamilton@nyu.edu
718-260-3792
New York University Polytechnic School of Engineering
Source:Eurekalert

Related biology news :

1. ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor
2. University of Houston researcher publishes textbook on tissue engineering
3. New professorship in tissue engineering links molecular engineering, marine biology
4. NJIT engineering professor spurs interest in sanitary landfills throughout Asia
5. Exquisitely engineered human vision featured in Optical Engineering
6. Climate engineering cant erase climate change
7. Engineering a better way to rebuild bone inside the body
8. UH awarded $2 million for new engineering professor
9. Elsevier selected publish official journal: Engineering in Agriculture, Environment & Food
10. Having problems with your engineering project? This book will be your lifesaver
11. UH petroleum engineering director wins SPE Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... ... March 27, 2017 , ... ... the fight against cancer, autoimmune disease and more through a single-cell precision engineering ... and proteomics analysis platform developed in the laboratory of Dr. James Heath ...
(Date:3/27/2017)... ATLANTA , March 27, 2017 Cousins Properties ... of the world,s leading biotechnology companies, has signed a 10-year, ... foot Class A office asset located in the Westshore submarket ... "We are thrilled that Amgen has chosen Corporate Center for ... Larry Gellerstedt , president and chief executive officer of ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small ... samples with limited tumor content in a large background of normal or wild ... the need for reliable detection of low abundance somatic mutations, particularly in small ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a ... ) and the US National Institutes of Health. Continue ... ... ...
Breaking Biology Technology: